Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Summary

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Timeline

Start

2015-02-24

Primary completion

2025-07-23

Completion

2026-01-31

Publications

• Goss GD, Darling GE, Westeel V, Nakagawa K, Massuti B, Perrone F, McLachlan SA, Kang JH, Wu YL, Dingemans AC, Dziadziuszko R, Greillier L, Okada M, Audigier-Valette C, Sugawara S, Nadal E, Catino A, Toffart AC, Mitsudomi T, Whittom R, Domine M, Yamamoto N, Molinier O, Morin F, Bradbury PA, Stockler MR, Ding K, O'Callaghan CJ. Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Mar;44(7):553-564. doi: 10.1200/JCO-25-01828. Epub 2026 Jan 13.

Drugs

Indications